In this issue of Rx Marketplace you will find an overview of recent capital market activity, final and proposed GILTI regulations, recent SEC comment letter trends, and updates to our on-line US GAAP Issues and Solutions for Pharmaceuticals and Life Sciences Companies Guide (PLS Guide).
In our spotlight section, we feature PwC’s Health Research Institute group, which supports executive decision makers by providing new intelligence and analysis on trends affecting health industries.
Our analysis of SEC comment letters identifies the frequency of topical areas addressed by the SEC staff and how their focus has evolved over time. We have updated the rankings and topics to include those comment letters issued to Health Industries companies through June 30, 2019.
PwC’s HRI was established in 2004 and supports executive decision makers by providing new intelligence and analysis on trends affecting health industries. HRI publishes ongoing coverage and analysis of new rules, regulations, and policy changes, such as changes to Medicare reimbursement for CAR-T therapies, and new digital health approval pathways at the FDA. Refer to the Top regulatory center news for further information and published articles.
US Pharmaceutical & Life Sciences Assurance Leader, PwC US